Brief report

Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin

Jenny Chia,¹ Kevin Thia,¹ Amelia J. Brennan,^{1,2} Margaret Little,³ Bronwyn Williams,³ Jamie A. Lopez,^{1,2,4} Joseph A. Trapani,^{1,2,4} and Ilia Voskoboinik^{1,2,5}

¹Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; ²Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; ³Queensland Children's Cancer Centre, Royal Children's Hospital, Brisbane, Australia; and Departments of ⁴Microbiology and Immunology and ⁵Genetics, University of Melbourne, Melbourne, Australia

Mutations in the perforin gene (*PRF1*) are a common cause of the fatal immune dysregulation disorder, familial hemophagocytic lymphohistiocytosis (type 2 FHL, FHL2). Here we report a female infant born with biallelic *PRF1* mutations: a novel substitution, D49N, and a previously identified in-frame deletion, K285del. We assessed the effects of each mutation on the cytotoxicity of human NK cells in which the expression of endogenous perforin was ablated with miR30based short hairpin (sh) RNAs. Both mutations were detrimental for function, thereby explaining the clinically severe presentation and rapidly fatal outcome. We demonstrate that D49N exerts its deleterious effect by generating an additional (third) N-linked glycosylation site, resulting in protein misfolding and degradation in the killer cell. Our data provide a rationale for treating some cases of type 2 familial hemophagocytic lymphohistiocytosis, based on the pharmacologic inhibition or modification of glycosylation. (*Blood.* 2012;119(7):1713-1716)

Introduction

Familial hemophagocytic lymphohistiocytosis (FHL) is a fatal autosomal recessive disorder of immune regulation.¹⁻⁵ Perforin (*PRF1*) mutations are a common cause, accounting for at least 30% of FHL cases.⁶⁻¹⁰ Perforin is expressed exclusively by cytotoxic lymphocytes, and its pore-forming activity is essential for the granule-mediated apoptosis of virus-infected and cancerous cells.¹¹ Although biallelic loss-of-function *PRF1* mutations result in aggressive FHL, which develops within weeks of birth, mutations that retain some activity are generally protective through infancy and early childhood but result in atypical late-onset FHL, hematologic malignancy, and/or life-threatening viral infections.¹²

In this study, we report a novel missense mutation, D49N, which was coinherited with a previously identified, yet uncharacterized, common deletion, K285del. We generated a novel functional assay in human NK cells to demonstrate that both mutations are detrimental to perforin-mediated cytotoxicity. Furthermore, we show that D49N introduces a novel N-linked glycosylation site that leads to protein misfolding and instability.

Methods

Perforin knockdown KHYG1 human NK cells

Perforin knockdown cell lines were created by overexpressing miR30-based shRNAs targeting the 3'-untranslated region of *PRF1*. The sequence of the 21mer constructs cloned into the retroviral pLMP-cherry vector was 5'-AUCCCGAUUCACCCUGUCCAA-3' and 5'-UCGGCUAUCGUUAGUGC-UAGU-3'. HEK293T cells were used to package the amphotropic retrovirus and the viral supernatant collected to transduce KHYG1 cells. Cherry red-positive cells were FACS sorted for selection of KHYG1 sh*PRF1* cells.

Submitted August 25, 2011; accepted December 6, 2011. Prepublished online as *Blood* First Edition paper, December 20, 2011; DOI 10.1182/blood-2011-08-374355.

The online version of this article contains a data supplement.

KHYG1 perforin complementation assays

For KHYG1 complementation assays, the coding sequence of human wild-type (WT) or mutated perforin was cloned into the retroviral murine stem cell virus green fluorescent protein (GFP) vector. HEK293T cells were used to package the amphotropic retrovirus and the viral supernatant collected to transduce KHYG1 sh*PRF1* cells. For selection of perforinexpressing KHYG1 sh*PRF1* cells, GFP⁺ cells were FACS sorted based on identical mean-relative fluorescence.

DNA sequencing, cell culture, and Western immunoblotting have been described previously¹² (for details see supplemental Methods, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article).

Results and discussion

We obtained peripheral blood from a female infant, the first-born of healthy, unrelated parents. She presented with fever, thrombocytopenia, and elevated bilirubin one day after birth, then rapidly developed neutropenia, hepatosplenomegaly, raised liver enzymes, ascites, and coagulopathy. At day 9, hemophagocytic lymphohistiocytosis (HLH) was diagnosed from a bone marrow aspirate showing pronounced hemophagocytosis, in addition to elevated ferritin, hypofibrinogenemia, and persistent pancytopenia. Therapy was commenced as per the HLH-2004 protocol, using etoposide, cyclosporine, and dexamethasone, but the infant did not respond and died on day 14 of progressive multiorgan failure. The *PRF1* gene was sequenced in the patient (and parents), revealing biallelic *PRF1* mutations: c.145G > A (exon 2) resulted in the D49N

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2012 by The American Society of Hematology






Figure 1. Identification of biallelic perforin mutations inherited by a female patient presenting with HLH. (A) Family tree indicating the perforin phenotype in each member of the patient's family. (B) Comparison of the perforin gene sequence of the patient and a normal WT control. One mutation was G145 > A, mapping to exon 2, and resulting in the substitution of aspartate 49 by asparagine (D49N), whereas the other was a deletion of nucleotides 853 to 855 in exon 3, resulting in the in-frame deletion of lysine 285 (K285del).

substitution, and an in-frame deletion c.[853_855delAAG] (exon 3) resulted in deletion of lysine 285 (K285del; Figure 1).

Because of limited patient material, cytotoxic activity of the patient's cytotoxic lymphocytes could not be tested. Instead, we designed a surrogate assay using the human NK cell line KHYG-1 to assess the effects of each *PRF1* mutation; previous studies of *PRF1* mutants have been limited to rodent cells.^{12,13} We created a perforin "knockdown" cell line using miR30-based shRNA constructs targeting the 3'-untranslated region of *PRF1* (sh*PRF1*). We found that reduced perforin protein expression correlated well with decreased killing of K562 target cells (not shown). Reintroducing human WT perforin into the cells (sh*PRF1* + WT) restored perforin levels and cytotoxic activity (Figure 2A).

We then examined the effects of the mutations on perforin-mediated cytotoxicity. All the lysines in the conserved sequence ²⁸²KKKKHK in perforin are encoded by AAG, making this region prone to replication slippage. Indeed, in-frame deletions have been reported in 9 unrelated patients (Figure 2Bi),^{4,7,14} but these mutations have never been studied functionally. We expressed K285del-perforin in KHYG1 sh*PRF1* cells and found that the deletion was detrimental to cytotoxicity (Figure 2Bii-iv). These results are consistent with clinical observations, as patients homozygous for deletions in this region invariably develop FHL within weeks to months of birth. The only K285del patient

presenting with late-onset FHL inherited a second *PRF1* mutation with partial activity (patient 9, Figure 2Bi).¹²


The second mutation, D49N, is novel. Because of a threonine (T51) 2 residues downstream of the mutation site, the asparagine-49 fulfilled the requirement for a consensus N-linked glycosylation site (N-x-S/T), which, by contrast with 2 conserved glycosylation sites (positions 205 and 548), is located centrally in the structurally labile MACPF domain.^{15,16} Similar to K285del, D49N did not rescue cytotoxicity in sh*PRF1* KHYG1 cells (Figure 2C). Consistent with glycan addition, D49N-perforin migrated slower on SDS-PAGE, and its expression level was lower than WT (Figure 2Ci-ii). The D49N-perforin was also undetectable by intracellular FACS staining using a different antibody (δ G9; supplemental Figure 1). To further corroborate abnormal folding, D49N-perforin was far more susceptible to trypsin digestion than WT-perforin (supplemental Figure 3).

To determine whether glycosylation per se contributed to the loss of cytotoxicity, a second mutation, T51D, was introduced with D49N to disrupt the glycosylation consensus sequence. As expected, this second mutation prevented the addition of the glycan and restored the protein's migration on SDS-PAGE (Figure 2Ci-ii; supplemental Figure 2). However, D49NT51D-perforin was still expressed at lower levels than WT-perforin (Figure 2Cii; supplemental Figure 1) and remained more susceptible to trypsin digestion (supplemental Figure 3), indicating that protein folding remained defective. Accordingly, although the ability to kill target K562 was significantly improved, it was still reduced compared with WT-perforin (Figure 2Ciii). This was not entirely surprising, as D49 is highly conserved across species. Indeed, the activity of an experimental mutant D49S was reduced compared with WT-perforin but was still significantly higher than that of D49N (Figure 2Ci-iii; supplemental Figure 2). To determine the intrinsic activity of D49NT51D-perforin, cells expressing identical levels of the D49NT51D and WT-perforin were sorted (supplemental Figure 4). Cytotoxicity of resultant KHYG1 cells was essentially identical, confirming gain of glycosylation as a pathogenic mechanism of D49N (Figure 2Ciii inset).

Overall, these data demonstrate that the D49N substitution has a marked adverse effect on perforin cytotoxicity because of the introduction of a new N-linked glycan, which in turn results in protein misfolding and degradation. The ability of both D49N and K285del to completely abolish perforin cytotoxicity was consistent with the clinical presentation at birth and rapid lethality in the affected patient.

Given the simplicity of the consensus sequence for Nglycosylation (N-x-S/T), we expected to identify a number of other disease-causing PRF1 mutations leading to gain of glycosylation. Indeed, our retrospective analysis revealed 7 such examples (Figure 2Civ). Patients inheriting such mutations in the homozygous state died of FHL at an early age.14,17-20 All of these mutations (including D49N) map near the center of the MACPF domain, immediately adjacent to the evolutionary conserved "bent" B-sheet,16 which is known to undergo marked conformational rearrangement when perforin inserts into the plasma membrane. The severe derangement of perforin structure predicted from this change was consistent with the early onset of FHL. Although less than 1.5% of known disease-causing missense mutations overall give rise to gains of glycosylation,²¹ this phenomenon appears somewhat more common in FHL2, affecting 4 of the approximately 50 PRF1 missense mutations to date. This difference may represent a statistical anomaly because of a relatively small number of catalogued perforin mutations, but may also reflect the inherent instability of a monomeric perforin, which does not permit a structural challenge as significant as gain of glycosylation.16

AKHYG1 assay




E:T ratio


B K285del

i Lysine deletion mutations

Patient	PRF1		Age of FHL onset	References
	allele 1	allele 2	Age of FHL onset	Reierences
1	K285del	K285del	3 months	Trizzino et al., 2008 Goransdotter Ericson et al., 200
2	K285del	K285del	3 months	Trizzino et al., 2008
3	KKHK284-7del	KKHK284-7del	1 month	Trizzino et al., 2008
4	K285del	T450M	4 months	Trizzino et al., 2008
5	KK284-5del	NR	2 months	Trizzino et al., 2008
6	K285del	NR	3 months	Trizzino et al., 2008
7	K285del	NR	6 months	Trizzino et al., 2008
8	K285del	NR	41 months	Trizzino et al., 2008
9	K285del	P201T	120 months	Trizzino et al., 2008 zur Stadt et al., 2005



C D49N and D49NT51D



i.,

Gain of glycosylation mutations

Patient	PRF1		Annual Fill annual	
	allele 1	allele 2	Age of FHL onset	References
1	G220S*	G2205*	1.5 months	Clementi et al., 2001
2	G220S*	L17fs	NR	Feldmann et al., 2002
3	G220S*	G220S*	2 months	Trizzino et al., 2008
4	G220S*	G2205*	2 months	Trizzino et al., 2008
5	\$168N*	T450M	6 years	Lu et al., 2009
6	S168N*	C393R	NR	Liu et al., 2011
7	W129S*	T433P	NR	Meeths, 2010, pers. comm.

*, putative gain of glycosylation mutation; NR, not reported; fs, frameshift

Figure 2. Patient's perforin mutations, D49N and K285del, are detrimental to NK cell cytotoxicity. (A) KHYG1 cells were virally transduced with nonsilencing (ns) shRNA or sh*PRF1* constructs to down-regulate perforin expression. Perforin expression was then restored in KHYG1 sh*PRF1* cells by virally transducing cells with WT-perforin construct (KHGY1 sh*PRF1*+ WT). KHYG1 sh*PRF1* cells were also transduced with the empty vector for control (KHYG1 sh*PRF1*+ GFP). (i) Western immunoblot shows the relative amounts of perforin expression in each of the stable KHYG1 to populations. (ii) Four-hour ⁵¹Cr release assays, against target K562 cells at the effector/taget (E:T) ratios indicated, show a 90% reduction in function in KHYG1 sh*PRF1* cells and full restoration in KHYG1 sh*PRF1*+ WT cells. Data are mean ± SE of 8 independent experiments. (Bi) Table shows patients 1 to 9 identified in the literature who inherited deletion mutations in the intensely basic (²⁸²KKKHK) region of *PRF1*. (ii-iv) KHYG1 sh*PRF1*. ells were virally transduced with K285del-perforin, sorted on the basis of identical mean GFP fluorescence (compared with KHYG1 sh*PRF1*+ GFP and KHYG1 sh*PRF1*+ WT cells), and then analyzed for perforin expression and cytotoxicity. For clarity, background levels seen for KHYG1 sh*PRF1*+ GFP cells were subtracted from total ⁵¹Cr release levels (to reflect the activity of reintroduced recombinant perforin) and standardized against WT-perforin at a 10:1 E/T ratio. Data are mean ± SE of 3 independent experiments. (Ci-iii) KHYG1 sh*PRF1*+ WT cells), and then analyzed for perforin expression and cytotoxicity. The values plotted represent standardized ⁵¹Cr release levels (a described in subpanels ii through iv. The data shown are mean ± SE of 7 independent experiments. (iii inset) Perforin-expressing KHYG1 sh*PRF1*+ cells were sorted to achieve identical protein expression and analyzed for perforin cytotoxicity. The values plotted represent standardized ⁵¹Cr release levels (as described in subpanels ii th

Gain of glycosylation mutations are associated with many other human diseases, including dysfibrinogenemia, antithrombin deficiency, and primary immunodeficiencies.²² For patients bearing these mutations, pharmaceuticals that inhibit glycosidases (eg, derivatives of castanospermine and NB-DNJ [N-butyl-deoxynojirimycin] or kifunensin)²³ have been shown to offer promising therapeutic benefits by inhibiting glycosylation and/or regulating the protein folding environment. Indeed, kifunensin significantly increased the activity of all NK cell lines. In contrast, castanospermine and NB-DNJ were detrimental for KHYG1 effector function (supplemental Figure 5).

Where appropriate, therapeutic approaches based on modifiers of glycosylation may therefore be explored as a temporary therapeutic intervention preceding potentially curative HSCT.

Acknowledgments

The authors thank Prof J.-L. Cassanova for providing the modifiers of glycosylation.

This study was supported in part by the Cancer Council Victoria (J.C.) and National Health and Medical Research Council of Australia (A.J.B., J.A.L., J.A.T., and I.V.).

Authorship

Contribution: J.C. designed and carried out the experiments, analyzed the data, and drafted the manuscript; K.T. performed genetic analyses; A.J.B. and J.A.L. helped design and conducted the experiments; M.L. and B.W. conducted the clinical studies; and J.A.T. and I.V. designed the study and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

References

- Dufourcq-Lagelouse R, Jabado N, Le Deist F, et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. Am J Hum Genet. 1999;64(1):172-179.
- Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. *Science*. 1999;286(5446):1957-1959.
- Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). *Cell*. 2003; 115(4):461-473.
- zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. *Hum Mol Genet*. 2005;14(6):827-834.
- zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. *Am J Hum Genet*. 2009; 85(4):482-492.
- 6. Janka GE. Hemophagocytic lymphohistiocytosis. *Hematology.* 2005;10(suppl 1):104-107.
- Goransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. *Am J Hum Genet*. 2001;68(3):590-597.
- Molleran Lee S, Villanueva J, Sumegi J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North

American families with haemophagocytic lymphohistiocytosis. *J Med Genet.* 2004;41(2):137-144.

- Voskoboinik I, Smyth MJ, Trapani JA. Perforinmediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006;6(12):940-952.
- zur Stadt U, Beutel K, Kolberg S, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat. 2006;27(1):62-68.
- 11. Brennan AJ, Chia J, Trapani JA, Voskoboinik I. Perforin deficiency and susceptibility to cancer. *Cell Death Differ.* 2010;17(4):607-615.
- Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. *Proc Natl Acad Sci U S A*. 2009; 106(24):9809-9814.
- Urrea Moreno R, Gil J, Rodriguez-Sainz C, et al. Functional assessment of perforin C2 domain mutations illustrates the critical role for calciumdependent lipid binding in perforin cytotoxic function. *Blood*. 2009;113(2):338-346.
- Trizzino A, zur Stadt U, Ueda I, et al. Genotypephenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. *J Med Genet.* 2008;45(1):15-21.
- Brennan AJ, Chia J, Browne KA, et al. Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. *Immunity.* 2011;34(6):879-892.

Correspondence: Ilia Voskoboinik, Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, VIC 3002, Australia; e-mail: ilia.voskoboinik@ petermac.org.

- Law RH, Lukoyanova N, Voskoboinik I, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. *Nature*. 2010; 468(7322):447-451.
- Clementi R, zur Stadt U, Savoldi G, et al. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. *J Med Genet*. 2001;38(9):643-646.
- Feldmann J, Le Deist F, Ouachee-Chardin M, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. *Br J Haematol.* 2002;117(4):965-972.
- Lu G, Xie ZD, Shen KL, et al. Mutations in the perforin gene in children with hemophagocytic lymphohistiocytosis. *Chin Med J (Engl)*. 2009; 122(23):2851-2855.
- Liu HX, Tong CR, Wang H, et al. [An analysis of etiological and genetic factors of a patient with familial hemophagocytic lymphohistiocytosis]. *Zhonghua Nei Ke Za Zhi.* 2011;50(2):132-135.
- Vogt G, Chapgier A, Yang K, et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. *Nat Genet.* 2005;37(7): 692-700.
- Vogt G, Vogt B, Chuzhanova N, Julenius K, Cooper DN, Casanova JL. Gain-of-glycosylation mutations. *Curr Opin Genet Dev.* 2007;17(3):245-251.
- Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov. 2002;1(1):65-75.